Chronic inflammation is associated with promotion of malignancy and tumor progression. Many tumors enhance the accumulation of myeloid-derived suppressor cells (MDSC), which contribute to tumor progression and growth by suppressing anti-tumor immune responses. Tumor-derived IL-1b secreted into the tumor microenvironment has been shown to induce the accumulation of MDSC possessing an enhanced capacity to suppress T cells. In this study, we found that the enhanced suppressive potential of IL-1b-induced MDSC was due to the activity of a novel subset of MDSC lacking Ly6C expression. This subset was present at low frequency in tumor-bearing mice in the absence of IL-1b-induced inflammation; however, under inflammatory conditions, Ly6C neg MDSC were predominant. Ly6C neg MDSC impaired NK cell development and functions in vitro and in vivo. These results identify a novel IL-1b-induced subset of MDSC with unique functional properties. Ly6C neg MDSC mediating NK cell suppression may thus represent useful targets for therapeutic interventions.
IL-1b regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function
Introduction
Epidemiological studies emphasize the role of chronic inflammation in the promotion of various types of cancers (reviewed in [1] ). The hallmarks of cancer-related inflammation include the presence at the tumor site of cytokines such as IL-1b, TNF-a, IL-6 and IL-23 [1] [2] [3] . IL-1b is a pleiotropic cytokine and induces the production by stromal and tumor-infiltrating cells of a cascade of molecules, including IL-6, prostaglandins and adhesion molecules that induce, sustain and expand the inflammatory response (reviewed in [3, 4] ). In the tumor microenvironment, IL-1b promotes angiogenesis [5, 6] , tumor invasiveness (reviewed in [7] ), carcinogenesis [8, 9] and affects immune function by many ways including indirectly through the accumulation of myeloid-derived suppressor cells (MDSC) [9] [10] [11] [12] .
MDSC represent a heterogeneous population of myeloid cells defined in the mouse as Gr-1 1
CD11b
1 cells encompassing granulocytes, macrophages, dendritic-like cells and early myeloid progenitors (reviewed in [13, 14] ). The often-observed expansion of MDSC during tumor progression is dependent on the tumor itself [15] and tumor-derived factors including IL-1b and S100A9/A8 (reviewed in [13, 14] ). In agreement with this, IL-1b-secretion by modified tumor cells leads to the enhanced accumulation of splenic MDSC that potently suppress T-cell proliferation and cytokine secretion [10] [11] [12] 16] . MDSC enhance tumor growth by several mechanisms including the suppression of the anti-tumor immune response. Mechanisms involving ROS, NO, L-arginine metabolism, nitrotyrosine, secretion of IL-10 and sequestration of cystine/cysteine [14, 16, 17] are involved in mediating the suppression of T cells, while TGF-b1 is involved in the suppression of NK cells [18] . Notably, the expression of ROS by MDSC has been correlated with the level of tumor-secreted IL-1b [11] .
Recent attention focused on the identification of tumorassociated MDSC subpopulations in different tumor models leading to the identification of a granulocytic polymorphonuclear neutrophil leukocyte (PMN-MDSC) subset as Ly6G [11, 19, 20] . Data from Bronte's group suggest that the immunosuppressive potential of MDSC cell subsets is sensitive to tumor-derived cytokines such as GM-CSF [21] . Together, these studies underscore the heterogeneity within the MDSC-pool with regard to their phenotype and immunosuppressive capacities and that the composition of this pool appears to be dynamically regulated by the tumor microenvironment. NK cells play a major role in tumor immunosurveillance [22, 23] . The majority of NK cells are generated in the bone marrow and after maturation seed peripheral organs. [24, 25] ).
Patients with diverse types of cancer (such as myelogenous leukemia and lung carcinoma) present with NK cell defects, including reduced NK cell numbers, reduced NK cell activity or reduced expression of activating receptors by NK cells [26, 27] . Although clinical studies and reports using mouse tumor models have described MDSC suppressing NK cell activities [18, 28, 29] , the role of specific MDSC subsets on NK cell suppression remains unclear.
In this study, we identify a novel subset of MDSC induced by IL-1b, which lack Ly6C expression and demonstrate enhanced capacity to inhibit NK cell function in vitro and in vivo.
Results

A novel PMN-MDSC subset lacking Ly6C expression
Inoculation of 4T1 or 4T1 cells over-expressing IL-1b (4T1/IL-1b, [11] ) subcutaneously into BALB/c Rag2 À/À mice resulted in significantly enlarged spleens in less than 7 days in both types of tumor-bearing mice due to a strong expansion of MDSC (identified as CD11b
1
Gr-1 1 cells) ( Fig. 1A and Supporting
Information Fig. 1 ). MDSC expansion was considerably faster in mice bearing 4T1/IL-1b tumors (Fig. 1A ), in line with previous results [11] . Regarding the distribution of polymorphonuclear (or granulocytic)-MDSC (PMN-MDSC; identified as Gr-1 Fig. 2B and C). We detected a similar predominance of Ly6C neg MDSC in the tumor mass, blood, lymph nodes, thymus of 4T1/IL-1b-tumor-bearing mice, while Ly6C low MDSC predominated in 4T1-tumor-bearing mice at these sites (Supporting Information Fig. 2D ).
Ly6C neg MDSC prevail under conditions of increased availability of IL-1b
Increasing the availability of IL-1b in 4T1-tumor-bearing mice either via treatment with multiple doses of recombinant IL-1b (rIL-1b; Fig. 2A (Fig. 2D ),
suggesting that tumor-derived IL-1b could substitute for the absence of host IL-1b.
Ly6C neg MDSC potently suppress T cells
The discovery of a novel subpopulation of MDSC prevailing in 4T1/IL-1b-tumor-bearing mice may explain the reported phenotypic differences of MDSC from these mice compared to those from 4T1-tumor-bearing mice [11] . It has been reported that splenic MDSC derived from 4T1/IL-1b-tumor-bearing mice expressed more ROS and were more effective T-cell suppressors [11] . We hypothesized that these differences may be attributable to the presence (and predominance) of the Ly6C neg MDSC subset.
Indeed, we found that Ly6C neg MDSC expressed higher levels of inducible nitric oxide synthase (iNOS or NOS2) and ROS than Ly6C low MDSC (Supporting Information Fig. 3A ). In line with Together, these data suggested the involvement of NK cells in the host anti-tumor response and that Gr-1 1 cells were involved in the inhibition of the Rag2-independent anti-tumor activity in 4T1/IL-1b-tumor-bearing mice.
4T1 and 4T1/IL-1b-tumors differentially affect host NK cells
We analyzed the NK cell compartment in mice bearing established tumors and detected a reduced number (po0.05) of CD122 1 NKp46 1 NK cells in the bone marrow of 4T1-(30% of control cell numbers) and 4T1/IL-1b-tumor-bearing mice (15% of control cell numbers) (Fig. 4A , left, and Supporting Information Fig. 4 ). We then analyzed the development of NK cells in the different mice. CD27 is a marker of immature NK cells, while sequential upregulation of CD11b and KLRG-1 expression is associated with NK cell maturation [25] . Using these markers, we found a similar percentage of CD27 1 NK cells in the bone marrow of all mice (Fig. 4B) ; however, NK cells from 4T1/IL-1b-tumorbearing mice expressed 5-10 times less CD27 protein than NK cells from the other mice (Fig. 4B) . Moreover, the tumor-bearing mice contained less CD11b 1 NK cells in the bone marrow (Fig. 4A (right) and B) indicating a block in the differentiation of NK cells in these mice.
In contrast to the BM, the total number of splenic NK cells was five-fold increased in both groups of tumor-bearing mice (Fig. 4A) (Fig. 5B, top) . Furthermore, transwell experiments revealed that NKG2D downregulation was cell-cell contact dependent (Fig. 5B, (Fig. 5B, bottom) . Together, these results indicated that MDSC subsets induce the downregulation of NKG2D on the cell surface of NK cells and that Ly6C neg MDSC were more potent in this process in vitro and in vivo.
Ly6C neg MDSC inhibit NK cell function in vivo
We next addressed whether the down modulation of NKG2D expression was associated with functional impairment of NK cells in vivo. We adoptively transferred enriched MDSC isolated from BM and spleen of 4T1-or 4T1/IL-1b-tumor-bearing mice, respectively, intravenously into naïve BALB/c mice and challenged them 2-3 days later with luciferase-expressing YAC-1 target cells (Luc-YAC-1). As few as 7-8 h thereafter, NK cell activity was significantly lower in mice that had received MDSC from the BM and spleen of 4T1/IL-1b-tumor-bearing mice as compared to those having received MDSC from 4T1-tumorbearing mice or Gr-1 1 CD11b 1 cells from naive mice (Fig. 5C ).
There was no clearance of Luc-YAC-1 cells in NK-deficient Rag2 À/À IL-2Rb À/À mice within the 8-h period confirming NK cells as the effectors (Supporting Information Fig. 5 ). To determine whether NK inhibition was associated with a specific 
IL-2Rb À/À mice (n 5 3-4). (C) 4T1/IL-1b tumor cells were injected into the footpad of Rag2
À/À mice (n 5 4); MDSC were eliminated by Gemcitabine treatment or depleted with antibodies against Gr-1. Tumor diameters were measured every 2-3 days. One representative experiment from 2 to 3 preformed is shown. Error bars show SD. Ã po0.05, calculated two-sided Student's t-test. did not affect NK cell activity (Fig. 5D ). We did not observe a reduction in the numbers of NK cells in the different mice (data not shown), indicating that the reduction in NK cell activity was due to functional inhibition and not elimination of host NK cells.
Discussion
Oncogenic transformation and cancer progression have been intimately linked with inflammatory conditions (reviewed in [1] ). Accordingly, we observed that 4T1 tumors developed faster in BALB/c mice when they over-expressed IL-1b, although both tumor lines exhibited similar growth kinetics in vitro (M.E. and R.N.A., unpublished observations and [11] ). MDSC are known to accumulate in tumor-bearing individuals, particularly under inflammatory conditions but they are also observed under various other pathological conditions, including infectious diseases [31] . The fact that multiple pathological conditions result in similar biological outcomes might explain the heterogeneity of MDSC but at the same time represents a challenge when studying these cells [31] . Understanding the pathways behind this heterogeneity under various conditions might allow unraveling the origin of their complexity. Here, we found that the enhanced accumulation of MDSC in mice bearing IL-1b-secreting 4T1 tumors was almost exclusively attributable to the expansion of a novel subset of MDSC. MDSC populations are mainly defined by their expression of Ly6C/G and CD11b, and this newly identified subset of PMN-MDSC was distinct from known MDSC subsets by its lack of Ly6C expression.
Our data provide strong evidence that IL-1b is involved in the regulation of the Ly6C neg MDSC subset and suggest that the predominance of Ly6C neg MDSC may enhance tumor progression in mice with 4T1/IL-1b tumors. Although the mode of action of this pleiotropic cytokine in this setting remains to be elucidated, its ability to enhance the survival of PMN [32] might in part explain the strong accumulation of MDSC in these mice. A regulatory role for Ly6C neg MDSC in mice with 4T1/IL-1b tumors is further supported by the delayed tumor growth after depletion of Gr-1 1 cells. IL-10-dependent regulatory capacities of PMN in the settings of bacterial infections have recently been demonstrated [33] . Interestingly, LPS and INFg activated MDSC from 4T1/IL-1b-tumor-bearing mice were shown to produce significantly more IL-10 than those from 4T1-tumor-bearing mice [16] ; yet, it remains to be shown whether this IL-10-dependent immune regulation occurs in the tumor environment [34] . Moreover, a novel subpopulation of human MDSC has recently been described possessing strong T-cell suppressive potential. This subset was induced from normal peripheral blood mononuclear cells using cytokine mixtures containing IL-1b [35] . In support of this, it has recently been shown that different tumor microenvironments harbor distinct subsets of tumor-associated macrophages that could be classified according to the ''M1'' (antitumor) versus ''M2'' (protumor) macrophage activation paradigm [36] and all of which could be derived from a common monocyte precursor population [36] . A similar plasticity has been reported to exist within tumor-associated neutrophils that could polarize under the influence of TGF-b present in the tumor-microenvironment toward antitumorigenic ''N1'' (when blocking TGF-b) versus protumorigenic ''N2'' (presence of TGF-b) subsets [37, 38] . Whether or not Ly6C neg -MDSC can be classified according to this paradigm requires further experimental investigation. NK cells are generally described as prototypic innate antitumor cells [27, 28] and an impaired NK cell compartment is associated with enhanced susceptibility to tumor development [39] [40] [41] . Consequently, a coherent ''survival'' strategy of tumors might involve impairing the activity of NK cells, which is indeed frequently observed in tumor-bearing individuals [18, 26-29, 42, 43] . The block in the development of NK cells from 4T1/IL-1b-tumor-bearing mice is similar to that observed in mice bearing EL4 tumors [44] and reminiscent of NK cells from transgenic mice expressing the CD27-ligand CD70 ectopically on all B cells [45] . The reduced level of CD27 expression by NK cells might thus be an indication of engagement of CD27 by its ligand CD70, suggesting that constitutive CD27-CD70 interactions might cause the observed block in NK cell development in 4T1/IL-1b-tumorbearing mice. As CD70 expression is restricted to activated T and B cells, its expression might be induced upon exposure to IL-1b. However, NK cells in CD70-tg mice were not functionally impaired and expressed high levels of NKG2D, suggesting that the functional inhibition of NK cells in 4T1/IL-1b-tumor-bearing mice is independent of the developmental defect.
Suppression of NK cell function in tumor-bearing mice has been shown to involve MDSC-derived cytokines including TGF-b1 [18] . Yet, gene expression profiles of Ly6C low MDSC and Ly6C neg MDSC showed no significant difference in TGF-b mRNA expression (M.E. and R.N.A., unpublished observations), indicating that in our mouse model the observed reduction of NKG2D expression by NK cells was independent of TGF-b. Interestingly, NK cells from mice that constitutively express the NKG2D-ligand Rae-1e exhibited a reduced cell-surface expression of NKG2D and were functionally impaired, while their development was not affected [46] . Our finding that cell-to-cell contact was necessary for MDSC-induced down-modulation of NKG2D supports the concept that NKG2D-NKG2D ligand interactions contribute to functional inhibition of NK cells. Nausch et al. demonstrated that some Mono-MDSC but not PMN-MDSC from RMA-S tumor-bearing mice activated NK cells via expression of the NKG2D-ligand Rae-1 [47] . Although we did not measure Rae-1 expression by Mono-MDSC, this subset was by far outnumbered by the considerably expanding Ly6C neg MDSC so that a potential activating activity of Mono-MDSC was likely overwhelmed by the suppressive activity of Ly6C neg MDSC.
Importantly, the RMA-S tumor model used by Nausch et al. differed from ours in that the granulocytic (PMN) MDSC in their studies expressed intermediate levels of Ly6C [47] , suggesting that RMA-S tumor cells may not create a heightened inflammatory tumor environment. In this work, we identified a novel MDSC subpopulation characterized by its lack of Ly6C expression and its inhibition of NK cell function. Our findings extend the complexity of this immunosuppressive myeloid cell population and demonstrate how inflammation, via the production of IL-1b, regulates MDSC phenotype and function.
Materials and methods
Mice BALB/c, BALB/c Rag2 À/À [48] and BALB/c Rag2 -/-IL-2Rb -/- [49] mice were obtained from Charles River. Mice were maintained under SPF conditions at the Institut Pasteur and used at 4-10 wk of age. In vivo experiments were approved by an institutional animal care committee at the Institut Pasteur and validated by the French Ministry of Agriculture. IL-1b -/-and IL-1Ra -/-mice were described previously [50] and kindly provided by Prof. Yoichiro Iwakura (Tokyo University). IL-1-deficient mice were housed under SPF conditions at the animal facilities of the faculty of Health Sciences, Ben-Gurion University. Mice were treated according to the NIH animal care guidelines adapted by the institutional animal committee.
Cells
The mammary carcinoma cell line 4T1was a kind gift of Dr. Fred Miller (Karmanos Cancer Institute, Detroit, MI, USA). 4T1/IL-1b were derived from 4T1 cells and maintained as described [11] . To generate Luc-YAC-1 cells YAC-1 cells were infected using TRIP Luc virus as described [51] . Luc-YAC-1 cells were maintained in RPMI-1640 medium complemented with 10% FBS, 10 À5 M 2-ME and 100 mg/mL penicillin.
Generation of tumors
Tumors were generated by injection of 4T1 and 4T1/IL-1b cells. 2 Â 10 5 tumor cells were injected into the footpad of recipient mice.
Tumor growth was assessed three times a wk using a caliper.
Flow cytometry analysis
Single-cell suspensions from the indicated organs were stained using commercially available antibodies listed in the Supporting Information Material and methods section, acquired on a FACSCanto II (FACSDiva software 5.02; BD Biosciences) and analyzed using FlowJo software (Tree Star). Dead cells were excluded using Live/Death fixable Aqua cell stain (Invitrogen).
Imaging NK lytic activity in vivo 
Adoptive transfer of MDSC
Cells were enriched or sorted as described, resuspended in 200 mL PBS and injected i.v. into recipient mice.
Depletion of Gr-1 1 cells and IL-1 injection
Gr-1 1 cells were depleted by injecting i.p. anti-Gr-1 antibodies (clone RB6-8C5; 250 mg) twice a wk. For Gemcitabine (Lilly) treatment, mice were injected i.p. twice a wk as described [17] . Recombinant IL-1b (Peprotech; 200 ng per mice) or recombinant IL-1Ra (Anakinra, Genetech; 50 mg/kg) were injected daily i.p.
Statistical analyses
Significant differences in results were determined using the twosided Student's t-test; a Ã po0.05 and ÃÃ po0.01. 
